Advertisement

Advertisement

Sarcoma
Solid Tumors
Issues in Oncology

Can FAP-Targeted Radioligand Therapy Benefit Patients With Advanced Sarcomas?

Fibroblast activation protein (FAP)-targeted radioligand therapy may be safe and effective in patients with progressive metastatic tumors, particularly advanced sarcomas, according to new findings presented by Lanzafame et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI)...

Sarcoma
Immunotherapy

Can Pembrolizumab Improve Outcomes in Soft-Tissue Sarcoma?

The PD-1 inhibitor pembrolizumab may offer benefit in patients with soft-tissue sarcoma, according to recent findings presented by Mowery et al at the 2024 ASCO Annual Meeting (Abstract 11504). Background Soft-tissue sarcoma is a rare type of cancer affecting muscles, fat, and other connective...

Sarcoma

Doublet for Previously Treated Patients With Advanced Leiomyosarcoma

In a phase Ib study reported in the Journal of Clinical Oncology, Van Tine et al established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma. Unesbulin is a small...

Sarcoma
Immunotherapy

T-Cell Therapy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

In a phase II trial (SPEARHEAD-1) reported in The Lancet, D’Angelo et al found that the T-cell therapy afamitresgene autoleucel showed activity in patients with previously treated HLA-A*02 and MAGE-A4–expressing advanced synovial sarcoma or myxoid round cell liposarcoma. As related by the...

Sarcoma

Nab-sirolimus in Advanced Malignant Perivascular Epithelioid Cell Tumors: AMPECT Trial Final Analysis

As reported in the Journal of Clinical Oncology by Wagner et al, final analysis of the phase II AMPECT trial has shown a median duration of response of more than 3 years in patients with advanced malignant perivascular epithelioid cell tumors treated with nab-sirolimus. The primary analysis of the...

Sarcoma

I Am Young and Fit—and Have Stage IV Alveolar Soft-Part Sarcoma

Except for my right thigh being bigger than my left thigh, there was no hint that I was harboring advanced alveolar soft-part sarcoma when I was diagnosed with the cancer in 2019. I initially chocked up the discrepancy in my legs to the vigorous workouts I had received during my cheerleading days,...

Sarcoma
Immunotherapy

Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma

Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer. Background About 13,000 new cases of soft-tissue...

Sarcoma
Immunotherapy
Cardio-oncology

Immunotherapy Outcomes in Patients With Primary Cardiac Soft-Tissue Sarcomas

In a U.S. multicenter retrospective analysis reported in JACC: CardioOncology, Amin H. Nassar, MD, and colleagues found that immune checkpoint inhibition resulted in mostly moderate activity in patients with primary cardiac soft-tissue sarcomas. Study Details The study included 24 patients with...

Sarcoma

Standard vs Histology-Tailored Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma

In an expanded cohort of a European trial reported in the Journal of Clinical Oncology, Alessandro Gronchi, MD, and colleagues found that histology-tailored neoadjuvant chemotherapy with trabectedin was noninferior in terms of disease-free survival to standard neoadjuvant anthracycline/ifosfamide...

Sarcoma

A Cancer Diagnosis at 19 Taught Me That It Takes Constant Vigilance to Stay Mentally Healthy

A lot of my experience with cancer is hazy to me. I was taking narcotics for pain around the clock when I was diagnosed with Ewing’s sarcoma in 2013, so there are some missing memories during those early days. I was 19 and a freshman in college when my symptoms started. I have always been active in ...

Sarcoma
Issues in Oncology

Machine-Learning Model May Accurately Calculate Chemotherapy Success in Patients With Osteosarcoma

Researchers have developed and trained a new machine learning model to calculate percent necrosis in patients with osteosarcoma, according to a novel study published by LiBrizzi et al in the Journal of Orthopaedic Research. Background A postchemotherapy percent necrosis calculation often helps...

Sarcoma

Efficacy of Radiotherapy in Rhabdomyosarcoma

In an analysis of data from two clinical trials and a soft-tissue sarcoma registry reported in the Journal of Clinical Oncology, Koscielniak et al identified which patients aged ≤ 21 years with localized rhabdomyosarcoma appeared to derive benefit from radiation therapy. Study Details The study...

Sarcoma

A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life

In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...

Sarcoma
Global Cancer Care

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...

Sarcoma

Localized Ewing Sarcoma: Interval-Compressed vs Standard-Timing Chemotherapy

As reported in the Journal of Clinical Oncology by Cash et al, 10-year follow-up of the Children’s Oncology Group Study AEWS0031 has shown a maintained event-free survival benefit with interval-compressed chemotherapy vs standard-timing chemotherapy in patients with localized Ewing sarcoma....

Sarcoma

PD-L1 Inhibition for Advanced Alveolar Soft-Part Sarcoma

In a phase II trial reported in The New England Journal of Medicine, Chen et al found that atezolizumab produced durable responses in patients with advanced alveolar soft-part sarcoma. As stated by the investigators: “Alveolar soft-part sarcoma is a rare soft-tissue sarcoma with a poor prognosis...

Sarcoma

Preoperative Chemoradiation With or Without Pazopanib in Nonrhabdomyosarcoma Soft-Tissue Sarcoma

As reported in the Journal of Clinical Oncology by Aaron R. Weiss, DO, and colleagues, follow-up in the Children’s Oncology Group/NRG Oncology phase II ARST1321 trial showed no differences in survival outcomes with the addition of pazopanib to preoperative chemoradiation in patients with...

Sarcoma
Immunotherapy

Activity and Toxicity of Pembrolizumab in Rare Sarcomas

In a French phase II basket trial (AcSé Pembrolizumab) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues investigated the activity and safety of pembrolizumab in patients with rare sarcomas. AcSé Pembrolizumab is an ongoing phase II multitumor study investigating the activity of...

Sarcoma

Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma

In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...

Sarcoma

Pathologic Complete Response and Outcomes in Localized Soft-Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy

In an analysis reported in JAMA Oncology, Wang et al found that pathologic complete response (pCR) was associated with improved outcomes among patients with localized soft-tissue sarcoma receiving neoadjuvant chemoradiotherapy or radiotherapy. The analysis included data from patients from two RTOG...

Sarcoma

Pathologic Complete Responses May Be Prognostic of Outcomes for Patients With Soft-Tissue Sarcoma

Researchers have discovered that pathologic complete responses may be associated with improved survival outcomes for patients with localized soft-tissue sarcoma who received preoperative chemoradiotherapy or radiotherapy, according to a novel study published by Wang et al in JAMA Oncology. The new...

Sarcoma

Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma

In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...

Sarcoma

The Beauty and the Beast of Cancer

The most humbling—and fortunate—experience I’ve had since I was diagnosed with osteosarcoma 13 years ago at the age of 43 was being treated in the pediatric wing of a major cancer center in New York City. It is pretty difficult to feel sorry for yourself when you are sitting next to a 14-year-old...

Sarcoma
Genomics/Genetics

ctDNA as a Prognostic Marker in Intermediate-Risk Rhabdomyosarcoma

In a study from the Children’s Oncology Group reported in the Journal of Clinical Oncology, Abbou et al found that measuring circulating tumor DNA (ctDNA) in intermediate-risk rhabdomyosarcoma was feasible and that the presence of ctDNA prior to treatment was associated with poorer prognosis. As...

Sarcoma

Addition of Anti–IGF-1R Antibody Ganitumab to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Metastatic Ewing Sarcoma

As reported in the Journal of Clinical Oncology by DuBois et al, the Children’s Oncology Group phase III AEWS1221 trial showed no event-free survival benefit with the addition of the anti–insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody ganitumab to interval-compressed...

Survivorship
Leukemia
Lymphoma
Sarcoma

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer Treated With Doxorubicin

In a study reported in the Journal of Clinical Oncology, Eric J. Chow, MD, MPH, and colleagues found that the use of dexrazoxane was associated with long-term protection of heart function in childhood cancer survivors who received doxorubicin for their cancer. According to the study investigators,...

Sarcoma
Solid Tumors
Lymphoma

MDM2 Inhibitor Milademetan in Advanced Liposarcoma, Solid Tumors, or Lymphomas

In a first-in-human, phase I, dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Mrinal M. Gounder, MD, and colleagues identified the dose and schedule for further evaluation of the oral MDM2 inhibitor milademetan in a population of patients with advanced...

Sarcoma
Gastrointestinal Cancer

ctDNA Analysis May Predict Optimal Treatment for Patients With GIST

Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented by Bauer et al during the January ASCO Plenary Series session (Abstract 397784). An...

Solid Tumors
Sarcoma
Immunotherapy

Novel Therapy Afamitresgene Autoleucel Shows Early Potential for Antitumor Activity

The adoptive T-cell receptor therapy afamitresgene autoleucel—which targets the MAGE-A4 cancer antigen—achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial, according to a novel study published by Hong et al in Nature Medicine. Initial...

Sarcoma

Hypofractionated 3-Week Course of Preoperative Radiotherapy for Soft-Tissue Sarcomas

In a single-center phase II trial (HYPORT-STS) reported in The Lancet Oncology, Guadagnolo et al found that a hypofractionated 3-week course of preoperative radiotherapy was safe in patients with soft-tissue sarcomas and may serve as an alternative to conventionally fractionated radiotherapy in...

Sarcoma
Immunotherapy

FDA Grants Approval to Atezolizumab in Treatment of Alveolar Soft-Part Sarcoma

On December 9, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft-part sarcoma (ASPS). Study ML39345 Efficacy was evaluated in Study ML39345...

Sarcoma

Comparison of Two Chemotherapy Regimens for Newly Diagnosed Ewing Sarcoma

As reported in The Lancet by Brennan et al, the European phase III EURO EWING 2012 trial found improved event-free survival with a standard U.S. chemotherapy regimen vs a standard European regimen in newly diagnosed patients with Ewing sarcoma. As stated by the investigators, “Internationally, a...

Sarcoma

Shorter Course of Hypofractionated Radiation Therapy Yields Comparable Results to Conventional Radiotherapy for Patients With Nonmetastatic Soft-Tissue Sarcoma

Patients with nonmetastatic soft-tissue sarcoma who need preoperative radiation therapy can safely receive hypofractionated treatment for 3 weeks instead of 5 weeks, with comparable tumor control and no increased risk of major complications in wound healing, according to a new study published by...

Breast Cancer
Sarcoma

Prevalence of and Risks for Thoracic Soft-Tissue Sarcomas in Breast Cancer Survivors

In a retrospective cohort study reported in The Lancet Oncology, Veiga et al found that receipt of radiotherapy was the strongest risk factor for development of thoracic soft-tissue sarcomas in U.S. breast cancer survivors; both hypertension and diabetes were significant risk factors for...

Sarcoma

Cabazitaxel in Advanced Dedifferentiated Liposarcoma

In a phase II EORTC Soft-Tissue and Bone Sarcoma Group trial reported in JAMA Oncology, Sanfilippo et al found that cabazitaxel showed activity in locally advanced, inoperable, or metastatic dedifferentiated liposarcoma. Study Details In the trial, 38 evaluable patients who had received no more...

Sarcoma
Immunotherapy

Durvalumab/Tremelimumab for Previously Treated Patients With Advanced Soft-Tissue and Bone Sarcomas

In a single-center phase II trial reported in The Lancet Oncology, Somaiah et al found that the combination of durvalumab and tremelimumab showed activity in a group of previously treated patients with advanced or metastatic soft-tissue and bone sarcomas of various subtypes. Study Details In the...

Sarcoma

Evaluating Strategies for Treating Pediatric Metastatic Rhabdomyosarcoma

In a report in the Journal of Clinical Oncology, Schoot et al provided findings from the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 and pooled findings of MTS 2008 with those of the concurrent BERNIE study, both of which evaluated strategies for the treatment of pediatric...

Sarcoma

Addition of Trabectedin to Doxorubicin in the First-Line Treatment of Advanced Leiomyosarcoma

In the French phase III LMS-04 trial reported in The Lancet Oncology, Pautier et al found that the addition of trabectedin to doxorubicin significantly prolonged progression-free survival as first-line treatment for patients with unresectable or metastatic leiomyosarcoma. Study Details In the...

Sarcoma

First Randomized Chemotherapy Study in Relapsed or Refractory Ewing Sarcoma Reports Modest Gains in Survival With High-Dose Ifosfamide

High-dose ifosfamide extended event-free and overall survival in patients with recurrent or primary refractory Ewing sarcoma compared with other commonly used chemotherapy regimens, according to the results of a randomized trial reported at the 2022 ASCO Annual Meeting by lead author Martin...

sarcoma

Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide

Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).

Sarcoma
Immunotherapy

Neoadjuvant Immunotherapy May Improve Survival for Patients With Soft-Tissue Sarcoma

In a phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), Keung et al reported at the 2022 ASCO Annual Meeting (Abstract LBA11501)....

Sarcoma

Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas

Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according to research presented by McCabe et al during the Plenary Session at the 2022 ASCO Annual Meeting...

Sarcoma

Addition of High-Dose Treosulfan and Melphalan to Consolidation in High-Risk Ewing Sarcoma

In a phase III trial (Ewing 2008R3) reported in the Journal of Clinical Oncology, Koch et al found that the addition of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells to consolidation did not improve event-free survival vs ...

Sarcoma

Selinexor in Previously Treated Advanced Dedifferentiated Liposarcoma

In the phase II/III SEAL trial reported in the the Journal of Clinical Oncology, Gounder et al found that selinexor significantly improved progression-free survival and time to subsequent treatment in previously treated advanced dedifferentiated liposarcoma, with the greatest benefit observed in...

Sarcoma

Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma

In the phase III TAPPAS trial reported in JAMA Oncology, Jones et al found that the addition of carotuximab to pazopanib did not improve progression-free survival in patients with advanced angiosarcoma. Carotuximab is an IgG1 antibody that binds endoglin, which is highly expressed on proliferating...

Immunotherapy
Sarcoma

PD-1 Inhibition in Patients With Classic or Endemic Kaposi Sarcoma

In a French phase II study reported in The Lancet Oncology, Delyon et al found that pembrolizumab produced a high response rate in patients with classic or endemic Kaposi sarcoma with progressive cutaneous extension requiring systemic treatment. As stated by the investigators, “Although the...

Sarcoma

Researchers Identify Trends in Treatment for Retroperitoneal Soft-Tissue Sarcoma

Researchers have published an analysis of strategies for treating retroperitoneal soft-tissue sarcoma, which has historically been understudied due to its rarity. The researchers say the trends they identified—particularly the convergence of certain treatments across centers—will help guide the way ...

Sarcoma
Issues in Oncology

The Virtues of Ruth: Gratitude, Advocacy, and Service

I still remember having to sit down with her three siblings on that afternoon. It was drizzling, cloudy, and cool—Mother Nature in agreement with the heaviness of what had just taken place. I held them tight. I knew the words I would utter next would change their lives forever. I paused for 10...

Solid Tumors
Sarcoma

Antibiotics After Endoprosthetic Reconstruction for Lower-Extremity Bone Tumors: Comparison of Two Intravenous Regimens

In a study reported in JAMA Oncology, researchers in the Prophylactic Antibiotic Regimens in Tumor Surgery Investigators group found that 5 days vs 1 day of postoperative intravenous antibiotic prophylaxis did not reduce the incidence of surgical site infection and was associated with more...

Sarcoma

Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumor

On November 22, 2021, sirolimus protein-bound particles for injectable suspension (albumin-bound) was approved for treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.1 Supporting Efficacy Data Approval was supported by findings in the...

Advertisement

Advertisement

Advertisement